A carregar...
First‐in‐Class Selective HDAC6 Inhibitor (ACY‐1215) Has a Highly Favorable Safety Profile in Patients with Relapsed and Refractory Lymphoma
LESSONS LEARNED: Oral selective HDAC6 inhibitors could allow for decreased toxicity compared to pan‐class inhibitors, and increased ease of use. ACY‐1215 is well tolerated and led to disease stabilization in 50% of patients treated on a twice‐daily dosing schedule. Rational drug combinations with AC...
Na minha lista:
| Publicado no: | Oncologist |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley & Sons, Inc.
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7930426/ https://ncbi.nlm.nih.gov/pubmed/33458921 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13673 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|